Suzanne Lentzsch

List of Publications by Year
in descending order

129 papers	6,657 citations	117625 34 h-index	64796 79 g-index
131 all docs	131 docs citations	131 times ranked	6230 citing authors

#	Article	IF	Citations
1	Flexor tenosynovectomy in carpal tunnel syndrome as a screening tool for early diagnosis of amyloidosis. Irish Journal of Medical Science, 2022, 191, 2427-2430.	1.5	1
2	Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis. American Journal of Hematology, 2022, 97, .	4.1	1
3	Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis. Leukemia and Lymphoma, 2022, , 1-5.	1.3	0
4	How do we manage t(11;14) plasma cell disorders with venetoclax?. British Journal of Haematology, 2022, 199, 31-39.	2.5	8
5	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 2022, 12, .	6.2	16
6	Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?. Journal of Clinical Oncology, 2022, 40, 3099-3102.	1.6	7
7	Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma. Blood, 2021, 137, 1754-1764.	1.4	7
8	Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?. Cancer, 2021, 127, 31-34.	4.1	4
9	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	10.7	92
10	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e105-e118.	10.7	136
11	Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial. EJHaem, 2021, 2, 375-384.	1.0	2
12	Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e674-e677.	0.4	5
13	Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood, 2021, 138, 2632-2641.	1.4	48
14	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 2021, 11, 10.	6.2	53
15	MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma. Blood, 2021, 138, 2662-2662.	1.4	0
16	Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (Î±CD38 mAb). Blood, 2021, 138, 1651-1651.	1.4	2
17	Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. Blood, 2021, 138, 2751-2751.	1.4	3
18	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 2021, 138, 1634-1634.	1.4	1

#	Article	IF	Citations
19	Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis. Blood, 2021, 138, 4726-4726.	1.4	0
20	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	6.2	62
21	Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 736-743.	0.4	5
22	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	5.0	46
23	Emerging drugs for the treatment of light chain amyloidosis. Expert Opinion on Emerging Drugs, 2020, 25, 299-317.	2.4	10
24	Systemic Amyloidosis due to Low-Grade Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 1027-1039.	2.2	8
25	Use of daratumumab in high risk multiple myeloma: A metaâ€analysis. EJHaem, 2020, 1, 267-271.	1.0	15
26	The clinical and pathological features of plasma cell myeloma post solid organ transplantation. American Journal of Hematology, 2020, 95, 1531-1541.	4.1	3
27	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 2020, 13, 115.	17.0	32
28	Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis. Acta Haematologica, 2020, 143, 373-380.	1.4	7
29	Diagnosis and management of systemic light chain AL amyloidosis. , 2020, 214, 107612.		3
30	Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2020, 10, 13.	6.2	5
31	Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e155-e157.	0.4	16
32	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia, 2020, 34, 2430-2440.	7.2	54
33	Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology, 2020, 38, 1455-1462.	1.6	31
34	Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clinical Cancer Research, 2020, 26, 3969-3978.	7.0	13
35	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTEÂ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). Blood, 2020, 136, 28-29.	1.4	83
36	Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 14-15.	1.4	9

#	Article	IF	Citations
37	REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 41-42.	1.4	48
38	Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 45-46.	1.4	4
39	Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).. Journal of Clinical Oncology, 2020, 38, 8510-8510.	1.6	15
40	Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs. Blood, 2020, 136, 24-24.	1.4	0
41	Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease. Blood, 2020, 136, 15-16.	1.4	2
42	Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 686-688.	0.4	16
43	Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 113-114.	3.0	2
44	One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 115-116.	3.0	24
45	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncology, The, 2019, 20, e302-e312.	10.7	290
46	Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 555-559.	0.4	8
47	Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. Expert Opinion on Investigational Drugs, 2019, 28, 445-462.	4.1	13
48	Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance. Blood, 2019, 134, 3161-3161.	1.4	2
49	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2019, 134, 3163-3163.	1.4	4
50	Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2019, 134, 3176-3176.	1.4	31
51	Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma. Blood, 2019, 134, 3072-3072.	1.4	2
52	Prospective study to measure the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma patients (PROMMIS).. Journal of Clinical Oncology, 2019, 37, 8030-8030.	1.6	2
53	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. Journal of Clinical Oncology, 2019, 37, 8040-8040.	1.6	1
54	Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations. Blood, 2019, 134, 1813-1813.	1.4	0

#	Article	IF	Citations
55	Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. Leukemia and Lymphoma, 2018, 59, 2465-2469.	1.3	9
56	Bone-Modifying Agents: Complicated to Use. Journal of Oncology Practice, 2018, 14, 469-470.	2.5	5
57	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer Journal, 2018, 8, 95.	6.2	59
58	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	3.5	225
59	Beyond NEOD001 for systemic light-chain amyloidosis. Blood, 2018, 132, 1992-1993.	1.4	18
60	IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. Blood Advances, 2018, 2, 492-504.	5.2	15
61	Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation. Haematologica, 2018, 103, 1688-1697.	3.5	14
62	Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies. Blood, 2018, 132, 3288-3288.	1.4	10
63	Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101. Blood, 2018, 132, 1003-1003.	1.4	2
64	Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101. Blood, 2018, 132, 958-958.	1.4	12
65	Low vs high dose carfilzomib (Cfz) with dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Results of SWOG S1304.. Journal of Clinical Oncology, 2018, 36, 8015-8015.	1.6	1
66	Factors associated with non-adherence to lenalidomide in patients with multiple myeloma.. Journal of Clinical Oncology, 2018, 36, e20031-e20031.	1.6	3
67	A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.. Journal of Clinical Oncology, 2018, 36, 8029-8029.	1.6	0
68	The Inhibition of Gck Affect MAPK Cascade in Multiple Myeloma. Blood, 2018, 132, 3202-3202.	1.4	0
69	Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 58-59.	3.0	55
70	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood, 2017, 130, 974-981.	1.4	391
71	The Critical Role of Imaging in the Management of Multiple Myeloma. Current Hematologic Malignancy Reports, 2017, 12, 168-175.	2.3	10
72	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncology, The, 2017, 18, e206-e217.	10.7	394

#	Article	IF	Citations
73	Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Therapeutic Advances in Hematology, 2017, 8, 55-70.	2.5	31
74	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. Journal of Clinical Oncology, 2017, 35, 8006-8006.	1.6	18
75	Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR).. Journal of Clinical Oncology, 2017, 35, 8036-8036.	1.6	4
76	Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Current Cancer Drug Targets, 2017, 17, 1-1.	1.6	50
77	Central nervous system involvement by multiple myeloma: A multiâ€institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	4.1	83
78	High-risk smoldering myeloma: Perspective on watchful monitoring. Seminars in Oncology, 2016, 43, 697-699.	2.2	6
79	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	10.7	1,866
80	Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma. Molecular Cancer Therapeutics, 2016, 15, 711-719.	4.1	16
81	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	1.3	30
82	Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. Blood, 2016, 128, 291-291.	1.4	1
83	Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor. Blood, 2016, 128, 3313-3313.	1.4	5
84	Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. Blood, 2016, 128, 3330-3330.	1.4	6
85	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. Blood, 2016, 128, 4468-4468.	1.4	11
86	Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 4523-4523.	1.4	1
87	Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2016, 128, 643-643.	1.4	12
88	Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2016, 128, 645-645.	1.4	46
89	Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. Blood, 2016, 128, 977-977.	1.4	15
90	Interferon Gamma (IFNÎ³)/STAT1 Signaling in Host Antigen Present Cells Suppresses MHC Class II-Dependent Presentation of Self-Antigens and Development of Graft Versus Host Disease (GVHD). Blood, 2016, 128, 2147-2147.	1.4	0

#	Article	IF	Citations
91	SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3. Blood, 2016, 128, 4477-4477.	1.4	0
92	Mini BEAM with Full-Dose of Melphalan (beaM) As a Conditioning Regimen for High Risk Patients with NHL Undergoing Autologous SCT. Blood, 2016, 128, 5834-5834.	1.4	0
93	Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool. Blood, 2016, 128, 2379-2379.	1.4	0
94	Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood, 2015, 126, 2284-2290.	1.4	201
95	Targeting cannabinoid receptorâ€2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption. Molecular Carcinogenesis, 2015, 54, 1796-1806.	2.7	9
96	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. Journal of Clinical Oncology, 2015, 33, 657-664.	1.6	330
97	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2015, 56, 3320-3328.	1.3	67
98	Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2015, 126, 188-188.	1.4	18
99	Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. Blood, 2015, 126, 3041-3041.	1.4	2
100	Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. Blood, 2015, 126, 508-508.	1.4	50
101	Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a randomized, phase III trial.. Journal of Clinical Oncology, 2015, 33, 8530-8530.	1.6	0
102	Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials. Blood, 2015, 126, 1975-1975.	1.4	0
103	IKZF1 Mutation Mediate Resistance to IMiDs in Human Hematopoietic Stem Cells. Blood, 2015, 126, 3003-3003.	1.4	0
104	Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas. Blood, 2015, 126, 593-593.	1.4	0
105	Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma. Blood, 2015, 126, 3009-3009.	1.4	0
106	Interferon-Gamma Signaling in the Pathogenesis of Idiopathic Pneumonia Syndrome Following Allogeneic Bone Marrow Transplantation. Blood, 2015, 126, 3075-3075.	1.4	0
107	Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM). Blood, 2015, 126, 2105-2105.	1.4	1
108	Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease. Clinical Cancer Research, 2014, 20, 5888-5897.	7.0	64

#	Article	IF	Citations
109	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, 2014, 123, 1826-1832.	1.4	327
110	Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy. Current Hematologic Malignancy Reports, 2013, 8, 277-283.	2.3	3
111	Lenalidomide and Dexamethasone Alone Is Equivalent To Lenalidomide and Dexamethasone With Autologous Stem Cell Transplant In Newly Diagnosed Multiple Myeloma: Interim Study Results Of a Randomized Trial. Blood, 2013, 122, 3180-3180.	1.4	1
112	Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study. Blood, 2013, 122, 4333-4333.	1.4	3
113	Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple Myeloma. Blood, 2013, 122, 690-690.	1.4	30
114	IFN-Î³/STAT1-Dependent Regulation Of Antigen Presenting Cell (APC) Function: Role In Graft-Versus-Host Disease (GVHD). Blood, 2013, 122, 3252-3252.	1.4	0
115	Inducible Silencing Of eIF4E Using a Tet-On System Results In Myeloma Growth In Vivo That Correlates With eIF4E Expression. Blood, 2013, 122, 3164-3164.	1.4	0
116	Knockdown Of Matrix Metalloproteinase 13 (MMP13) In 5TGM1 Multiple Myeloma Cells Inhibits Development Of Lytic Bone Lesions In Vivo. Blood, 2013, 122, 879-879.	1.4	0
117	Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood, 2012, 119, 4205-4214.	1.4	64
118	The application and biology of immunomodulatory drugs (IMiDs) in cancer. , 2012, 136, 56-68.		65
119	Effect of matrix metallopeptidase 13 (MMP13) on multiple myeloma (MM) cells, osteoclast (OCL) activity, and bone resorption.. Journal of Clinical Oncology, 2012, 30, 8099-8099.	1.6	0
120	IMiD immunomodulatory compounds block C/EBPÎ² translation through eIF4E down-regulation resulting in inhibition of MM. Blood, 2011, 117, 5157-5165.	1.4	89
121	Targeting the Microtubular Network as a New Antimyeloma Strategy. Molecular Cancer Therapeutics, 2011, 10, 1886-1896.	4.1	20
122	Recent advances of IMiDs in cancer therapy. Current Opinion in Oncology, 2010, 22, 579-585.	2.4	30
123	Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood, 2010, 115, 605-614.	1.4	74
124	C/EBPÎ² regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood, 2009, 114, 3890-3898.	1.4	73
125	KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Molecular Cancer Therapeutics, 2008, 7, 1494-1505.	4.1	49
126	The histone deacetylase inhibitor, PXD101, potentiates bortezomibâ€induced antiâ€multiple myeloma effect by induction of oxidative stress and DNA damage. British Journal of Haematology, 2007, 139, 385-397.	2.5	118

#	Article	IF	Citations
127	Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 2006, 107, 3098-3105.	1.4	141
128	Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood, 2005, 105, 3833-3840.	1.4	53
129	In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood, 2002, 100, 3311-3318.	1.4	92